Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Management of the Patient with Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 14 of 21

Patient Discussion: Other Treatments

The patient points out that the guide refers to drugs called ARBs as well as ACEIs. He mentions that if taking an ACEI is good, why are you not prescribing an ARB as well as an ACEI?

Discussion of answers:

A.Incorrect. The addition of a combination of ACEI/ARB to standard therapy for patients with stable ischemic heart disease has no clinical benefits and is associated with increased harms.

B.Incorrect. Results from the ONTARGET trial indicate that ACEIs do not significantly differ from ARBs in any measured clinical outcome.

C.Correct. Available evidence indicates there are no clinical benefits and a significant increase in harms for an ACEI/ARB combination in this patient population.

D.Incorrect. Available evidence indicates there are no clinical benefits and a significant increase in harms for an ACEI/ARB combination in this patient population.